Steven Shak - Concepedia

Author

Steven Shak

Genomic Health (United States)ORCID

Also Known As

A Tsiatis, Abdou, Yara, Hayes, Daniel F, S SHAK, S Shak, S. Shak, Schilsky, Richard L., Steven Shak

218

Publications

40.8K

Citations

H-Index

131

Concepts

All Affiliations

Genomic Health (United States)University of Pittsburgh University of California, San Francisco Dana-Farber Cancer Institute NSABP Foundation

About

Steven Shak is an author at Genomic Health (United States) specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	44	7.4K
2	Public Health	9	9	266
3	Health Sciences	7	7	179
4	Natural Sciences	7	7	1.4K
5	Engineering	4	4	313

Steven Shak

Publications

40.2K

Citations

H-Index

Page 1

	Year	Citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, New England Journal of Medicine	2001	11.4K
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer Soonmyung Paik, Steven Shak, Gong Tang, New England Journal of Medicine	2004	6.3K
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease Melody Cobleigh, Charles L. Vogel, Debu Tripathy, Journal of Clinical Oncology	1999	2.8K
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer Soonmyung Paik, Gong Tang, Steven Shak, Journal of Clinical Oncology	2006	2.6K
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer Charles L. Vogel, Melody Cobleigh, Debu Tripathy, Journal of Clinical Oncology Breast OncologySingle AgentMedicineCancer ManagementPharmacology	2002	1.8K
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience Andrew D. Seidman, Clifford A. Hudis, Mary Kathryn Pierri, Journal of Clinical Oncology	2002	1.5K
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Kathy S. Albain, William E. Barlow, Steven Shak, The Lancet Oncology 21-Gene Recurrence ScoreBreast OncologyMedicineRandomised TrialPathology	2009	1.4K
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study Mitch Dowsett, Jack Cuzick, Christopher Wale, Journal of Clinical Oncology	2010	718
Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Steven Shak, Daniel J. Capon, Renate Hellmiss, Proceedings of the National Academy of Sciences Dna AnalysisMolecular BiologyNucleic Acid Amplification TestGene DeliveryRecombinant Human Dnase	1990	711
A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling Eric A. Klein, Matthew R. Cooperberg, Cristina Magi‐Galluzzi, European Urology Gleason Grade HeterogeneityUrologyOncologyGenitourinary CancerTumor Heterogeneity	2014	650

Page 1